Carolina Wealth Advisors LLC Has $221,000 Position in Cencora, Inc. (NYSE:COR)

Carolina Wealth Advisors LLC boosted its stake in shares of Cencora, Inc. (NYSE:COR) by 270.3% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 985 shares of the company’s stock after purchasing an additional 719 shares during the quarter. Carolina Wealth Advisors LLC’s holdings in Cencora were worth $221,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of COR. Concord Wealth Partners acquired a new stake in shares of Cencora in the third quarter valued at $30,000. SYSTM Wealth Solutions LLC bought a new stake in Cencora in the 2nd quarter valued at $36,000. Ashton Thomas Securities LLC bought a new stake in shares of Cencora during the 3rd quarter valued at $41,000. Fairscale Capital LLC bought a new stake in shares of Cencora during the 2nd quarter valued at $54,000. Finally, Modus Advisors LLC bought a new stake in shares of Cencora during the 4th quarter worth $54,000. 97.52% of the stock is owned by institutional investors.

Cencora Price Performance

Shares of COR opened at $237.74 on Thursday. Cencora, Inc. has a twelve month low of $214.77 and a twelve month high of $253.27. The company has a current ratio of 0.88, a quick ratio of 0.53 and a debt-to-equity ratio of 4.84. The firm’s fifty day simple moving average is $237.79 and its 200-day simple moving average is $233.67. The firm has a market capitalization of $45.95 billion, a price-to-earnings ratio of 31.66, a PEG ratio of 1.54 and a beta of 0.49.

Cencora Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, November 29th. Stockholders of record on Friday, November 15th were given a $0.55 dividend. The ex-dividend date of this dividend was Friday, November 15th. This represents a $2.20 annualized dividend and a dividend yield of 0.93%. This is an increase from Cencora’s previous quarterly dividend of $0.51. Cencora’s payout ratio is presently 29.29%.

Insiders Place Their Bets

In related news, Chairman Steven H. Collis sold 50,000 shares of the stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the completion of the sale, the chairman now owns 326,557 shares in the company, valued at $79,670,111.29. This trade represents a 13.28 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Silvana Battaglia sold 1,678 shares of Cencora stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $228.72, for a total transaction of $383,792.16. Following the transaction, the executive vice president now directly owns 20,329 shares in the company, valued at $4,649,648.88. The trade was a 7.62 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 94,696 shares of company stock worth $22,862,734. Insiders own 15.80% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. Mizuho initiated coverage on Cencora in a research report on Wednesday, December 4th. They set an “outperform” rating and a $280.00 price objective for the company. StockNews.com downgraded Cencora from a “strong-buy” rating to a “buy” rating in a report on Friday, September 20th. Bank of America reiterated a “neutral” rating and issued a $245.00 target price (down from $275.00) on shares of Cencora in a report on Wednesday, September 18th. Evercore ISI lifted their target price on Cencora from $250.00 to $285.00 and gave the stock an “outperform” rating in a report on Thursday, November 7th. Finally, Wells Fargo & Company reduced their price objective on Cencora from $249.00 to $237.00 and set an “equal weight” rating for the company in a research note on Friday, December 13th. Two analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat.com, Cencora currently has an average rating of “Moderate Buy” and an average price target of $275.60.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.